{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"36"}],"units":"Participants"}],"description":"The phase Ib portion of the study is designed to determine the MTD of romidepsin and lenalidomide.","groups":[{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 10 mg","id":"OG000","title":"Dose Level -1"},{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 15 mg","id":"OG001","title":"Dose Level 1"},{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 25 mg","id":"OG002","title":"Dose Level 2"},{"description":"Romidepsin 10 mg/m\\^2/Lenalidomide 25 mg","id":"OG003","title":"Dose Level 3"},{"description":"Romidepsin 14 mg/m\\^2/Lenalidomide 25 mg","id":"OG004","title":"Dose Level 4"}],"paramType":"NUMBER","populationDescription":"No participants treated on Dose Level -1","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Dose Limiting Toxicities/DLTs","type":"PRIMARY","unitOfMeasure":"DLT's"}